Next Week’s ‘Big Genomic Moment’ and How to Play it

I don’t know if you’ve been following the FIFA World Cup in Russia.

I got up early to watch England versus Tunisia.

On paper, England should have run away with it.

Harry Kane put them a goal ahead early.

From there it was a fairly scratchy affair.

Though Tunisia grappled, dived and kept passing back, they didn’t look remotely close to scoring.

Until they did — 10 minutes from half time, from a Kyle Walker penalty inside the box.

It looked like England may well end up with a hugely deflating draw, as the second half dragged on.

Until ‘one big moment’ in injury time, right at the death.

Harry Kane came to the rescue with a second goal, headed in from a corner just moments from the final whistle.

You see this a lot in sport.

Whether it’s a set shot in front of a goal on the siren, the spirited tailender that makes a tonne of runs, or that one piece of wizardry from the fly-half that unlocks the game…

Indeed, that’s the beauty of sport…

No matter who’s playing better, ‘one magic moment’ can completely change the game.

Even when the game seems over. 

It’s not necessarily fair.

And often, it’s that one moment that makes all the difference.

Which brings me to exponential investing…

As you’ve seen so far this week, I believe we’re approaching…

‘One Magic Moment’ in genomics

And I’ve selected four magic stocks I believe are best positioned to ride this moment.

We’re going to dig into these plays next week.

They’re risky.

At the moment, three of the four have little to no earnings.

No sales records to analyse.

Stock analysts aren’t watching them.

But, if my research is right, a magic moment is approaching.

And, if I’m right, there could be SERIOUS money to be made if you anticipate this moment before it goes mainstream.

Biotech ‘great leaps’ are perhaps the most rewarding stock investment areas, full stop.

But there are also graveyards full of biotech investments gone wrong.

Take Vivus Pharmaceuticals, for instance.

The company’s flagship diet drug, Qsymia, was once touted as a massive disrupter of the diet industry. Early investors rose the price all the way up to $28.54.

Its commercial performance turned out to be an unmitigated disaster.

It became one of the most shorted stocks in biotech.

Those $28 shares are now worth around 80 cents.

These step changes tend to occur after years of costly research, combative peer reviews, and long hours of experimentation.

All in the hope that something truly world-changing could result.

And even if it does, that’s just the start.

You then have to try to get your discovery commercialised. Deal with unscrupulous patent trolls who try to steal your glory. And government regulators that can make or break your decades of research at the stroke of a pen.

This is the case with the four stocks we’re going to showcase next week.

With each stock, the catalyst is blockchain.

Blockchain, in my opinion, is about to make the genomic transformations we’ve seen since 2003 look relatively tame.

And because of the new project we’ll be looking at next week, the next few years are going to see a wave of genomic leaps…leaps that could radiate and reach all the sciences that gravitate around molecular biology.

And leaps that could potentially make you rich, if you pick the stocks doing the leaping early on.

Tune in next week for more…

This week in Money Morning

Chances are you don’t always pay enough attention to emerging markets. That’s not a criticism, it’s just that all investors tend to have a ‘home bias’ when it comes to stocks. But don’t overlook some of the BIGGEST potential trades in coming years. Read Harje’s take in Monday’s Money Morning, here.

Have you been caught up in all the shocking twists coming from the current US administration? It can be almost hypnotising. But Harje argues that, for an investor, the 24-hour news cycle can throw up a lot more noise than signal. Read why in Tuesday’s Money Morning, here.

Will your job be the next taken by the unstoppable AI wave? Artificial intelligence isn’t knocking at the door of stock analysts, yet — and we’re thankful for it. But you might be surprised at the next profession under threat of AI disruption. Read the details here.

Maybe you found the perfect stock buy and are ready for what’s next. Maybe you cannot find a suitable purchase and are antsy to pay and play. Whatever the situation, jumping at a new position may not be the best move. Read why here.

The 80s saw the rise and subsequent crash of IBM’s profits. IBM managed to rise like a phoenix with the advent of the internet economy in the 1990s. Can Telstra ride a similar wave back to prominence today? Read here why Harje isn’t so sure this wave will be the lifeline Telstra is hoping it will.


Ryan Dinse,
Editor, Exponential Stock Investor

Ryan Dinse is an Editor at Money Morning.

He has worked in finance and investing for the past two decades as a financial planner, senior credit analyst, equity trader and fintech entrepreneur.

With an academic background in economics, he believes that the key to making good investments is investing appropriately at each stage of the economic cycle.

Different market conditions provide different opportunities. Ryan combines fundamental, technical and economic analysis with the goal of making sure you are in the right investments at the right time.

Ryan's premium publications include:

Money Morning Australia